159 related articles for article (PubMed ID: 37454871)
1. Hepatocyte-secreted FAM3D ameliorates hepatic steatosis by activating FPR1-hnRNP U-GR-SCAD pathway to enhance lipid oxidation.
Hu Y; Li J; Li X; Wang D; Xiang R; Liu W; Hou S; Zhao Q; Yu X; Xu M; Zhao D; Li T; Chi Y; Yang J
Metabolism; 2023 Sep; 146():155661. PubMed ID: 37454871
[TBL] [Abstract][Full Text] [Related]
2. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis.
Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J
Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663
[TBL] [Abstract][Full Text] [Related]
3. NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.
Yang W; Wang J; Chen Z; Chen J; Meng Y; Chen L; Chang Y; Geng B; Sun L; Dou L; Li J; Guan Y; Cui Q; Yang J
Diabetes; 2017 Jul; 66(7):1819-1832. PubMed ID: 28411267
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
5. Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis.
Liu X; Hou S; Xiang R; Hu C; Chen Z; Li N; Yan H; Yu X; Li X; Chi Y; Yang J
Metabolism; 2022 Nov; 136():155292. PubMed ID: 35995281
[TBL] [Abstract][Full Text] [Related]
6. DR region of NKAα1 is a target to ameliorate hepatic lipid metabolism disturbance in obese mice.
Sun HJ; Tan JX; Shan XD; Wang ZC; Wu ZY; Bian JS; Nie XW
Metabolism; 2023 Aug; 145():155579. PubMed ID: 37127227
[TBL] [Abstract][Full Text] [Related]
7. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
[TBL] [Abstract][Full Text] [Related]
9. Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice.
Chen Z; Ding L; Yang W; Wang J; Chen L; Chang Y; Geng B; Cui Q; Guan Y; Yang J
Diabetes; 2017 May; 66(5):1185-1197. PubMed ID: 28246289
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes.
Wang XY; Lu LJ; Li YM; Xu CF
Life Sci; 2022 Nov; 308():120925. PubMed ID: 36057399
[TBL] [Abstract][Full Text] [Related]
12. FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes.
Zhang X; Yang W; Wang J; Meng Y; Guan Y; Yang J
Metabolism; 2018 Apr; 81():71-82. PubMed ID: 29221790
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide ameliorates hepatic steatosis via retinoic acid receptor-related orphan receptor α-mediated autophagy pathway.
Yu X; Bian X; Zhang H; Yang S; Cui D; Su Z
IUBMB Life; 2023 Oct; 75(10):856-867. PubMed ID: 37310057
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (
Wu M; Lo TH; Li L; Sun J; Deng C; Chan KY; Li X; Yeh ST; Lee JTH; Lui PPY; Xu A; Wong CM
Elife; 2023 Aug; 12():. PubMed ID: 37580962
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of FAM3D (Family With Sequence Similarity 3, Member D), A Novel Chemokine, Attenuates Neutrophil Recruitment and Ameliorates Abdominal Aortic Aneurysm Development.
He L; Fu Y; Deng J; Shen Y; Wang Y; Yu F; Xie N; Chen Z; Hong T; Peng X; Li Q; Zhou J; Han J; Wang Y; Xi J; Kong W
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1616-1631. PubMed ID: 29853563
[TBL] [Abstract][Full Text] [Related]
17. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
18. Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease.
Lee KC; Hsieh YC; Chan CC; Sun HJ; Huang YH; Hou MC; Lin HC
Lab Invest; 2019 Jul; 99(8):1203-1216. PubMed ID: 30918325
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
[TBL] [Abstract][Full Text] [Related]
20. High-Fat Diet-Induced DeSUMOylation of E4BP4 Promotes Lipid Droplet Biogenesis and Liver Steatosis in Mice.
Wang S; Yang M; Li P; Sit J; Wong A; Rodrigues K; Lank D; Zhang D; Zhang K; Yin L; Tong X
Diabetes; 2023 Mar; 72(3):348-361. PubMed ID: 36508222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
